Is APUS or ARCT more undervalued in 2026?

CirclFi compares Apimeds Pharmaceuticals US, Inc (APUS) and Arcturus Therapeutics Holdings (ARCT) using 13 institutional-grade valuation models. APUS has a Quality of Company score of 4.8/10 while ARCT scores 6.7/10.

Which is a better buy — APUS or ARCT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do APUS and ARCT valuations compare?

APUS at $1.41 and ARCT at $7.92 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

APUS vs ARCT Valuation Comparison 2026 — Intrinsic Value Analysis

APUS

Pharmaceutical Preparations

Apimeds Pharmaceuticals US, Inc

Quality

4.8

out of 10

Value Trap

SAFE

Price

$1.41

Last close

Models

7/13

Active

ARCT

Pharmaceutical Preparations

Arcturus Therapeutics Holdings

Quality

6.7

out of 10

Value Trap

SAFE

Price

$7.92

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	APUS Fair Value	APUS Upside	ARCT Fair Value	ARCT Upside
Bayesian DCF	Intrinsic	$0.41	-70.8%	$5.10	-35.6%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$6.62	+369.5%	$1.95	-72.2%
Dynamic NAV	Asset-Based	$4.65	+230.1%	$9.69	+22.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for APUS vs ARCT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

APUS vs ARCT — Which Stock Is More Undervalued?

ARCT scores higher with a 6.7/10 quality rating vs APUS's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Apimeds Pharmaceuticals US, Inc (APUS) and Arcturus Therapeutics Holdings (ARCT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

APUS currently trades at $1.41 with a QOC of 4.8/10, while ARCT trades at $7.92 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).